Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: Rationale and design of the Assessment with a double Randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and Clopidogrel after des implantation, and (2) Treatment Interruption versus Continuation, 1 year after stenting (ARCTIC) study

American Heart Journal

Volumn 161, Issue 1, 2011, Pages

  Collet, Jean Philippe ^a   Cayla, Guillaume ^b   Cuisset, Thomas ^c   Elhadad, Simon ^d   Rangé, Grégoire ^e   Vicaut, Eric ^f   Montalescot, Gilles ^a,f  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b DEPARTMENT OF NEUROLOGY   (France)

^c TIMONE HOSPITAL   (France)

^d Centre hospitalier de Lagny Marne la Vallee   (France)

^e Department of Cardiologie   (France)

^f Centre de Recherches Cliniques Psychanalytique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PRASUGREL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OPEN STUDY; PARALLEL DESIGN; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS; STENT THROMBOSIS; STROKE; THROMBOCYTE FUNCTION;

EID: 78650387026     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.09.029     Document Type: Article

References (34)

1. Kushner F.G., Hand M., and Smith S.C. Jr 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 54 2009 2205 2241
2. Silber S., Albertsson P., and Aviles F.F. Guidelines for percutaneous coronary interventions. The task force for percutaneous coronary interventions of the European Society of Cardiology Eur Heart J 26 2005 804 847
3. Bonello L., Tantry U., and Marcucci R. Consensus and future directions on the definition of high on-treatment platelet reactivity to ADP J Am Coll Cardiol 56 2010 112 116
4. Holmes D.R., Dehmer G.J., and Kaul S. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning", a Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association J Am Coll Cardiol 56 2010 321 341
5. Breet N.J., van Werkum J.W., and Bouman H.J. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation (POPular Study) JAMA 303 2010 754 762
6. Hulot J.S., Collet J.P., and Silvain J. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C192 loss-of-function allele or proton pump inhibitor co-administration: a systematic meta-analysis J Am Coll Cardiol 56 2010 134 143
7. Hochholzer W., Trenk D., and Fromm M.F. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement J Am Coll Cardiol 55 2010 2427 2434
8. Smith S.C. Jr, Allen J., and Blair S.N. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute Circulation 113 2006 2363 2372 (Pubitemid 43947981)
9. http://www.fda.gov/Drugs/DrugSafety/Postmarket FDSCreoPcipwapmotdAa, DrugSafetyInformationforPatientsandProviders/ucm203888.htm. Last accessed April 28.
10. Bonello L., Dignat-George F., and Camoin-Jau L. Adjusted clopidogrel loading dose to platelet reactivity measure decrease the rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multi centric randomized, prospective study J Am Coll Cardiol 51 2008 1404 1411 (Pubitemid 351447314)
11. Valgimigli M., Campo G., and de Cesare N. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study Circulation 119 2009 3215 3222
12. van Werkum J.W., van der Stelt C.A., and Seesing T.H. A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention Thromb Haemost 11 2006 2516 2518
13. Price M.J., Endemann S., and Gollapudi R.R. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000 (Pubitemid 351844676)
14. Grove E.L., Hvas A.M., and Johnsen H.L. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease Thromb Haemost 103 2010 1245 1253
15. Collet J.P., Silvain J., and Landivier A. Dose-effect of clopidogrel re-loading in patients already on 75 mg maintenance dose: the RELOAD study Circulation 118 2008 1225 1233
16. Bassand J.P., Hamm C.W., and Ardissino D. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes Eur Heart J 28 2007 1598 1660 (Pubitemid 350305871)
17. Cutlip D.E., Windecker S., and Mehran R. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351 (Pubitemid 46685903)
18. Rao S.V., Jollis J.G., and Harrington R.A. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes JAMA 292 2004 1555 1562 (Pubitemid 39314961)
19. Montalescot G., White H.D., and Gallo R. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention N Engl J Med 355 2006 1006 1017 (Pubitemid 44343544)
20. Mega J.L., Close S.L., and Wiviott S.D. Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
21. Malinin A., Pokov A., and Spergling M. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12R rapid analyzer: The VERIfy Thrombosis risk ASsessment (VERITAS) study Thromb Res 119 2007 277 284 (Pubitemid 44918092)
22. Price M., Coleman J., and Steinhubl S.R. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers Am J Cardiol 98 2006 681 684 (Pubitemid 44233472)
23. Grines C.L., Bonow R.O., and Casey D.E. Jr Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians Circulation 115 2007 813 818 (Pubitemid 46294748)
24. Eisenstein E.L., Anstrom K., and Kong D. Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation JAMA 297 2007 158 168 (Pubitemid 46089732)
25. Ho P.M., Peterson E.D., and Wang. Incidence of Death and Acute Myocardial Infarction Associated With Stopping Clopidogrel After Acute Coronary Syndrome JAMA 299 5 2008 532 539 (Pubitemid 351222546)
26. Daemen J., Wenaweser P., and Tsuchida K. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678 (Pubitemid 46281313)
27. Yusuf S., Mehta S.R., and Zhao F. Early and late effects of clopidogrel in patients with acute coronary syndromes Circulation 107 7 2003 966 972 (Pubitemid 36258718)
28. van Werkum J.W., Heestermans A.A., and Zomer A.C. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry J Am Coll Cardiol 53 16 2009 1399 1409
29. Collet J.P., Montalescot G., and Steg P.G. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial Arch Cardiovasc Dis 102 6-7 2009 485 496
30. Park S.J., Park D.W., and Kim Y.H. Duration of dual antiplatelet therapy after implantation of drug-eluting stents N Engl J Med 2010 10.1056/NEJMe1001266
31. Bhatt DL, Flather MD, Hacke W, et al. Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial 2007;49:1982-1988.
32. Shuldiner A.R., O'Connell J.R., and Gurbel P.A. Influence of CYP2C19 Polymorphism on Antiplatelet Effects of Clopidogrel and Long-term Recurrent Ischemic Event Occurrence JAMA 302 8 2009 849 858
33. Angiolillo D.J., Fernandez-Ortiz A., and Bernardo E. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease Diabetes 55 2006 780 784 (Pubitemid 43343236)
34. Wykrzykowska J.J., Warnholtz A., and de Jaeger P. Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study J Thromb Thrombolysis 28 4 2009 410 417